Mr. Andre Larente reports

DIAGNOS ANNOUNCES A MULTI-YEAR CONTRACT WITH JUAREZ HEALTH & MEDICAL TOURISM CLUSTER

Diagnos Inc. has signed a seven-year contract with the Juarez Health & Medical Tourism Cluster, headquartered in Ciudad Juarez, Chihuahua, Mexico.

The Juarez Health & Medical Tourism Cluster will be the distributor of Diagnos's CARA (computer-assisted retina analysis) platform in Mexico. Its close ties to the northern region's health care network, as well as in Mexico's private and public sectors, makes it the ideal partner for Diagnos. Mexico has a very high rate of diabetes and hypertension amongst its population, making it a prime market territory for Diagnos.

"Patient safety and quality of medical services is the lifeblood of our organization. Joining forces with Diagnos aligns perfectly with our permanent goal of making Ciudad Juarez a global health destination," said Dr. Lorenzo Soberanes, president and board member of the Juarez Health & Medical Tourism Cluster. "We plan to allocate Diagnos's turnkey solution in at least 20 sites in the first two years of the contract. The deployment will begin on Sept. 25, and we plan to distribute Diagnos's technology in five points of care by the end of 2021."

"We look forward to supporting Juarez Health & Medical Tourism Cluster in its mission by supplying our AI-based [artificial intelligence] technology and screen their patients in real time so they can be monitored and treated by specialists," noted Andre Larente, president and chief executive officer of Diagnos. "Diagnos is proud to have its technology recognized and adopted as a next-generation solution for patient screening at Juarez Health & Medical Tourism Cluster members. This agreement is an important step in commercializing the CARA platform in Mexico and Latin America."

About Diagnos Inc.

Diagnos is a publicly traded Canadian corporation dedicated to the early detection of critical health problems based on its Flaire artificial intelligence platform. Flaire allows for the quick modification and development of applications such as CARA. CARA's image enhancement algorithms provide sharper, clearer and easier-to-analyze retinal images. CARA is a cost-effective tool for real-time screening of large volumes of patients. CARA has been cleared for commercialization by the following regulators: Health Canada, the United States Food and Drug Administration, CE (Europe), COFEPRIS (Mexico) and Saudi Food and Drug Authority (Saudi Arabia).

We seek Safe Harbor.